Trial Profile
Safety and efficacy of nivolumab in patients with metastatic non-clear cell renal cell carcinoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology